Differenzialdiagnose Vaskulitis und Vaskulopathie aus dermatologischer Sicht

Zusammenfassung

Vaskulopathien und Vaskulitiden stellen diagnostisch und therapeutisch eine interdisziplinäre Herausforderung dar. Zugrunde liegen unterschiedliche pathophysiologische Mechanismen, die zu vielfältigen klinischen Krankheitsbildern führen können und therapeutisch unterschiedliche Ansätze erlauben. Sowohl Vaskulitiden als auch Vaskulopathien müssen nicht zwangsläufig mit einer Systembeteiligung einhergehen, sondern können auch als rein kutane Varianten auftreten. Aufgrund mangelnder pathognomonischer Laborparameter ist die Diagnose häufig klinisch zu stellen. Dieser Artikel soll den differenzialdiagnostischen Blick, insbesondere auf die kutanen Manifestationsformen bei Vaskulopathien und Vaskulitiden, schärfen.

Abstract

Vasculopathies and vasculitides pose an interdisciplinary challenge in terms of diagnosis and therapy. They are based on different pathophysiological mechanisms that can lead to clinical symptoms and allow different therapeutic approaches. Neither vasculitides nor vasculopathies have necessarily to be associated with systemic involvement, but can also occur as purely cutaneous variants. Due to the lack of pathognomonic laboratory parameters, the diagnosis is often clinical. This article is intended to focus on the differential diagnostic view, particularly in the case of cutaneous manifestations of vasculitis and vasculopathies.

Fazit

Vaskulitiden und Vaskulopathien stellen sowohl klinisch als auch differenzialdiagnostisch eine Herausforderung dar. Oftmals zeigt sich eine kutane Beteiligung, die aufgrund der charakteristischen Effloreszenzen, deren Lokalisation und Verteilungsmuster auf die zugrunde liegende Ursache hinweisen kann. Der dermatologische Blick kann nicht per se die Ursache und Art der vorliegenden Vaskulitis oder Vaskulopathie benennen, er kann aber einen Beitrag zur schnelleren Diagnose und Beurteilung liefern.

Schlüsselwörter

Vaskulitis - Vaskulopathie - Livedovaskulopathie - Differenzialdiagnose

Keywords

vasculitis - vasculopathy - livedoid vasculopathy - differential diagnosis

Publikationsverlauf

Eingereicht: 08. April 2022

Angenommen nach Revision: 30. Mai 2022

Artikel online veröffentlicht:
01. September 2023

• Literatur

• 1 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11 DOI: 10.1002/art.37715. (PMID: 23045170)
• 2 Mitschang C, Görge T. Diagnosis and treatment of vasculitic ulcerations. Hautarzt 2020; 71: 870-879 DOI: 10.1007/s00105-020-04694-0. (PMID: 32997218)
• 3 Sunderkötter CH, Zelger B, Chen K-R. et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70: 171-184 DOI: 10.1002/art.40375. (PMID: 29136340)
• 4 Sunderkötter C, Roth J, Bonsmann G. Leukocytoclastic vasculitis. Hautarzt 2004; 55: 759-783 quiz 784–5 DOI: 10.1007/s00105-004-0760-1. (PMID: 15257403)
• 5 Díaz-Pérez JL, De Lagrán ZM, Díaz-Ramón JL. et al. Cutaneous polyarteritis nodosa. Semin Cutan Med Surg 2007; 26: 77-86 DOI: 10.1016/j.sder.2007.02.003. (PMID: 17544958)
• 6 Tsianakas A, Ehrchen JM, Presser D. et al. Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol 2009; 61: 701-706 DOI: 10.1016/j.jaad.2008.11.913.
• 7 Gonzalez CD, Florell SR, Bowen AR. et al. Histopathologic vasculitis from the periulcer edge: A retrospective cohort study. J Am Acad Dermatol 2019; 81: 1353-1357 DOI: 10.1016/j.jaad.2019.04.011.
• 8 Pillebout E, Sunderkötter C. IgA vasculitis. Semin Immunopathol 2021; 43: 729-738 DOI: 10.1007/s00281-021-00874-9. (PMID: 34170395)
• 9 Schirmer JH, Aries PM, de Groot K. et al. S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 2017; 76: 77-104 DOI: 10.1007/s00393-017-0394-1. (PMID: 29204681)
• 10 Aries PM, Hellmich B, Gross WL. Diagnosis und therapy of ANCA-associated vasculitis. Dtsch Med Wochenschr 2006; 131: 443-446 DOI: 10.1055/s-2006-932541. (PMID: 16493569)
• 11 Sunderkötter C. Vaskulitis und Vaskulopathien. Plewig G, Ruzicka T, Kaufmann R, Hertl M. Braun-Falco’s Dermatologie, Venerologie und Allergologie; Berlin, Heidelberg: Springer Berlin Heidelberg; 2018. DOI: 10.1007/978-3-662-49544-5_64
• 12 Marzano AV, Raimondo MG, Berti E. et al. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. In: Clin Rev Allergy Immunol. 2017: 428-438 DOI: 10.1007/s12016-017-8616-5 (PMID: 28578472)
• 13 Berden AE, Ferrario F, Hagen EC. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636 DOI: 10.1681/ASN.2010050477. (PMID: 20616173)
• 14 Aasarød K, Bostad L, Hammerstrøm J. et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 2001; 16: 953-960 DOI: 10.1093/ndt/16.5.953.
• 15 Hauer HA, Bajema IM, van Houwelingen HC. et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62: 1732-1742 DOI: 10.1046/j.1523-1755.2002.00605.x. (PMID: 12371974)
• 16 Kluger N, Pagnoux C, Guillevin L. et al. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol 2008; 159: 615-620 DOI: 10.1111/j.1365-2133.2008.08725.x. (PMID: 18647311)
• 17 Ratzinger G, Zelger BG, Carlson JA. et al. Vasculitic wheel – an algorithmic approach to cutaneous vasculitides. J Dtsch Dermatol Ges 2015; 13: 1092-1117 DOI: 10.1111/ddg.12859. (PMID: 26513067)
• 18 Munera-Campos M, Bielsa I, Martínez-Morillo M. et al. Manifestations, clinical course and prognostic markers in cutaneous polyarteritis nodosa. J Dtsch Dermatol Ges 2020; 18: 1250-1259 DOI: 10.1111/ddg.14271. (PMID: 33015940)
• 19 de Boysson H, Guillevin L. Polyarteritis Nodosa Neurologic Manifestations. Neurol Clin 2019; 37: 345-357 DOI: 10.1016/j.ncl.2019.01.007. (PMID: 30952413)
• 20 Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol 2010; 49: 750-756 DOI: 10.1111/j.1365-4632.2010.04522.x. (PMID: 20618492)
• 21 Ricotti C, Kowalczyk JP, Ghersi M. et al. The diagnostic yield of histopathologic sampling techniques in PAN-associated cutaneous ulcers. Arch Dermatol 2007; 143: 1334-1336 DOI: 10.1001/archderm.143.10.1334. (PMID: 17938356)
• 22 Bauzá A, España A, Idoate M. Cutaneous polyarteritis nodosa. Br J Dermatol 2002; 146: 694-699 DOI: 10.1046/j.1365-2133.2002.04624.x. (PMID: 11966708)
• 23 Diaz-Perez JL, Schroeter AL, Winkelmann RK. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol 1980; 116: 56-58 (PMID: 6101533)
• 24 Rogalski C, Sticherling M. Panarteritis cutanea benigna – an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. Int J Dermatol 2007; 46: 817-821 DOI: 10.1111/j.1365-4632.2007.02975.x. (PMID: 17651163)
• 25 Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 1997; 136: 706-713 (PMID: 9205503)
• 26 Boehm I, Bauer R. Low-dose methotrexate controls a severe form of polyarteritis nodosa. Arch Dermatol 2000; 136: 167-169 DOI: 10.1001/archderm.136.2.167. (PMID: 10677090)
• 27 Lobo I, Ferreira M, Silva E. et al. Cutaneous polyarteritis nodosa treated with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2008; 22: 880-882 DOI: 10.1111/j.1468-3083.2007.02478.x.
• 28 Buttgereit F, Dejaco C, Matteson EL. et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315: 2442-2458 DOI: 10.1001/jama.2016.5444. (PMID: 27299619)
• 29 Wang X, Hu ZP, Lu W. et al. Giant cell arteritis. Rheumatol Int 2008; 29: 1-7 DOI: 10.1007/s00296-008-0662-0. (PMID: 18716781)
• 30 Tago M, Oishi T, Makio S. et al. Tongue Necrosis: An Atypical Sign of Giant-cell Arteritis. Intern Med 2021; 60: 3347-3348 DOI: 10.2169/internalmedicine.7096-21. (PMID: 33967137)
• 31 Chua-Aguilera CJ, Möller B, Yawalkar N. Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clin Rev Allergy Immunol 2017; 53: 371-393 DOI: 10.1007/s12016-017-8632-5. (PMID: 28752373)
• 32 Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med 2015; 53: 128-132 DOI: 10.1515/rjim-2015-0017. (PMID: 26402981)
• 33 McRorie ER, Ruckley CV, Nuki G. The relevance of large-vessel vascular disease and restricted ankle movement to the aetiology of leg ulceration in rheumatoid arthritis. BrJ Rheumatol 1998; 37: 1295-1298 DOI: 10.1093/rheumatology/37.12.1295. (PMID: 9973152)
• 34 Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital Dermatol Venereol 2018; 153: 243-255 DOI: 10.23736/S0392-0488.18.05872-8. (PMID: 29368864)
• 35 Bywaters EG, Scott JT. The Natural History of Vascular Lesions in Rheumatoid Arthritis. J Chronic Dis 1963; 16: 905-914 DOI: 10.1016/0021-9681(63)90139-5. (PMID: 14058397)
• 36 Sayah A, English 3rd JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53: 191-209 quiz 210–2 DOI: 10.1016/j.jaad.2004.07.023. (PMID: 16021111)
• 37 Sanchez NP, Winkelmann RK, Schroeter AL. et al. The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases. J Am Acad Dermatol 1982; 7: 599-605 DOI: 10.1016/s0190-9622(82)70139-2. (PMID: 6754776)
• 38 Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 1992; 26: 441-448 DOI: 10.1016/0190-9622(92)70069-r. (PMID: 1564151)
• 39 Kuhn A, Schuppe HC, Ruzicka T. et al. Rare cutaneous manifestaions of lupus erythematosus. A clinical overview. Hautarzt 2000; 51: 818-825 DOI: 10.1007/s001050051224. (PMID: 11116845)
• 40 Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg 2011; 15: 8-14 DOI: 10.2310/7750.2010.09033. (PMID: 21291650)
• 41 Koh JH, Park Y, Lee J. et al. Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sjögren’s syndrome: results from the KISS cohort study. Clin Exp Rheumatol 2021; 39: 114-122
• 42 Lawley TJ, Moutsopoulos HM, Katz SI. et al. Demonstration of circulating immune complexes in Sjögren’s syndrome. J Immunol 1979; 123: 1382-1387 (PMID: 469255)
• 43 Sunderkötter C, Michl C. Cutaneous alterations in vasculitides: Part 2: Special aspects of diseases of large, medium and small vessels. Internist (Berl) 2019; 60: 805-813 DOI: 10.1007/s00108-019-0642-3. (PMID: 31300830)
• 44 Mitschang C, Görge T. Purpura pigmentosa progressiva. Phlebologie 2017; 46: 358-360
• 45 Sherertz EF. Pigmented purpuric eruptions. Semin Thromb Hemost 1984; 10: 190-195 DOI: 10.1055/s-2007-1004422. (PMID: 6474193)
• 46 Sardana K, Sarkar R, Sehgal VN. Pigmented purpuric dermatoses: an overview. Int J Dermatol 2004; 43: 482-488 DOI: 10.1111/j.1365-4632.2004.02213.x. (PMID: 15230884)
• 47 Iwatsuki K, Aoshima T, Tagami H. et al. Immunofluorescence study in purpura pigmentosa chronica. Acta Derm Venereol 1980; 60: 341-345 (PMID: 6163282)
• 48 Schober SM, Peitsch WK, Bonsmann G. et al. Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis. J Dtsch Dermatol Ges 2014; 12: 1112-1119 DOI: 10.1111/ddg.12520.
• 49 Laufer F. The treatment of progressive pigmented purpura with ascorbic acid and a bioflavonoid rutoside. J Drugs Dermatol 2006; 5: 290-293
• 50 Weishaupt C, Strölin A, Kahle B. et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy – a multicentre analysis. J Eur Acad Dermatol Venereol 2019; 33: 1784-1791 DOI: 10.1111/jdv.15639. (PMID: 31009111)
• 51 Schiffmann M-L, Dissemond J, Erfurt-Berge C. et al. S1-Leitlinie Diagnostik und Therapie der Livedovaskulopathie. J Dtsch Dermatol Ges 2021; 19: 1667-1678 DOI: 10.1111/ddg.14520_g. (PMID: 34811901)
• 52 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79 DOI: 10.1016/S2352-3026(15)00251-3.
• 53 Baker WFJR, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 2008; 22: 33-52 v-vi DOI: 10.1016/j.hoc.2007.10.007. (PMID: 18207064)
• 54 Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab. J Dermatolog Treat 2017; 28: 564-566 DOI: 10.1080/09546634.2017.1282599. (PMID: 28084106)
• 55 Francès C, Niang S, Laffitte E. et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785-1793 DOI: 10.1002/art.21041. (PMID: 15934071)
• 56 Crome CR, Rajagopalan S, Kuhan G. et al. Antiphospholipid syndrome presenting with acute digital ischaemia, avascular necrosis of the femoral head and superior mesenteric artery thrombus. BMJ Case Rep 2012; 2012 DOI: 10.1136/bcr-2012-006731.
• 57 Cervera R, Tektonidou MG, Espinosa G. et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20: 174-181 DOI: 10.1177/0961203310395052. (PMID: 21303834)